FR14C0056I1 - - Google Patents

Info

Publication number
FR14C0056I1
FR14C0056I1 FR14C0056C FR14C0056I1 FR 14C0056 I1 FR14C0056 I1 FR 14C0056I1 FR 14C0056 C FR14C0056 C FR 14C0056C FR 14C0056 I1 FR14C0056 I1 FR 14C0056I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33457481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0056(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0056I1 publication Critical patent/FR14C0056I1/fr
Application granted granted Critical
Publication of FR14C0056I2 publication Critical patent/FR14C0056I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
FR14C0056C 2003-05-27 2014-07-22 Composes, preparations et methodes de traitement ou de prevention de la rosacee Active FR14C0056I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47361103P 2003-05-27 2003-05-27
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
PCT/US2004/016799 WO2004105703A2 (en) 2003-05-27 2004-05-26 Compounds, formulations, and methods for treating or preventing rosacea

Publications (2)

Publication Number Publication Date
FR14C0056I1 true FR14C0056I1 (cs) 2014-08-22
FR14C0056I2 FR14C0056I2 (fr) 2016-12-23

Family

ID=33457481

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0056C Active FR14C0056I2 (fr) 2003-05-27 2014-07-22 Composes, preparations et methodes de traitement ou de prevention de la rosacee

Country Status (22)

Country Link
US (13) US7439241B2 (cs)
EP (3) EP2388007B1 (cs)
CN (4) CN101816793B (cs)
AT (1) ATE530185T1 (cs)
AU (1) AU2004242967C1 (cs)
CA (1) CA2530938C (cs)
CY (3) CY1112242T1 (cs)
DK (3) DK1631293T4 (cs)
ES (3) ES2547336T3 (cs)
FR (1) FR14C0056I2 (cs)
HR (1) HRP20150957T1 (cs)
HU (3) HUE027616T2 (cs)
IL (1) IL172612A (cs)
LT (1) LT2815748T (cs)
LU (1) LU92462I2 (cs)
MX (1) MXPA05014107A (cs)
NO (1) NO333468B1 (cs)
NZ (1) NZ544300A (cs)
PL (3) PL1631293T5 (cs)
PT (3) PT2815748T (cs)
SI (3) SI2388007T1 (cs)
WO (1) WO2004105703A2 (cs)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
BRPI0511519A (pt) * 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
WO2006085840A1 (en) * 2005-01-31 2006-08-17 Kross Robert D Skin-protective polymer for use in teat care compositions
DE202005002183U1 (de) 2005-02-04 2005-04-14 Beiersdorf Ag Hautverwöhnende Cremelotion
CA2600384C (en) * 2005-03-30 2016-08-30 Revance Therapeutics, Inc. Compositions and methods for treating acne
ES2675228T3 (es) 2005-06-17 2018-07-09 Wisconsin Alumni Research Foundation Preparaciones tópicas de vasoconstrictores y métodos para proteger a las células durante la quimioterapia y radioterapia del cáncer
WO2007002447A2 (en) * 2005-06-23 2007-01-04 Bioform Medical, Inc. Compositions for treating rosacea
FR2894474B1 (fr) * 2005-12-12 2008-04-11 Galderma Res & Dev Gel depigmentant hydroalcoolique
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
SI2182960T1 (sl) 2007-07-27 2014-07-31 Galderma Laboratories Inc. Spojine, formulacije in postopki za zmanjĺ anje koĺ˝nih gub, meäśkanja in poveĺ anja
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP3498299A1 (en) 2007-11-16 2019-06-19 Aclaris Therapeutics, Inc. Compositions and methods for treating purpura
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
WO2009082452A1 (en) 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
WO2010014552A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
WO2010085753A1 (en) * 2009-01-23 2010-07-29 Jr Chem, Llc Rosacea treatments and kits for performing them
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
JP6172938B2 (ja) * 2009-05-15 2017-08-02 レクロ・ファーマ，インコーポレーテッド デクスメデトミジンの舌下組成物およびその使用方法
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
RU2530604C2 (ru) * 2009-05-29 2014-10-10 Галдерма Ресерч Энд Девелопмент Инъецируемая комбинация агонистов адренергических рецепторов с наполнителями для уменьшения кожных реакций на инъекцию
CN102711471A (zh) * 2009-10-26 2012-10-03 戈德玛制药股份公司 治疗或预防急性红斑的方法
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
CA2792649A1 (en) * 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
ES2627405T3 (es) * 2010-03-26 2017-07-28 Galderma Research & Development Composiciones que comprenden brimonidina para el tratamiento del eritema
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US8911713B2 (en) 2010-06-30 2014-12-16 Galderma Research & Development Method for preventing or treating skin tumor
US20130190317A1 (en) * 2010-08-06 2013-07-25 Galderma Research & Development Snc Combination of compounds for treating or preventing skin diseases
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
SI2444068T1 (sl) 2010-10-21 2014-11-28 Galderma S.A. Brimodin gel sestavek
MX2013004472A (es) * 2010-10-21 2013-10-25 Galderma Sa Composicion topica de gel.
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
MX385460B (es) * 2010-11-16 2025-03-18 Allergan Inc Composiciones farmaceuticas que comprenden (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol.
ES2618907T3 (es) * 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
SG190859A1 (en) 2010-12-20 2013-07-31 Colgate Palmolive Co Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
WO2012083397A1 (en) 2010-12-22 2012-06-28 Silvestre Labs Químia E Farmaceutica Ltda. Guanabenz-containing compound for the treatment of primary cutaneous amyloidosis
WO2012112566A1 (en) * 2011-02-15 2012-08-23 Allergan, Inc. Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
CN102260608B (zh) * 2011-06-23 2012-07-04 江苏安惠生物科技有限公司 灵芝肥皂及其制备方法
EP2731606A1 (en) * 2011-07-14 2014-05-21 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
JP2014530846A (ja) 2011-10-19 2014-11-20 ガルデルマ ソシエテ アノニム ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2013078151A1 (en) 2011-11-21 2013-05-30 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
EP2809300A1 (en) * 2012-02-02 2014-12-10 Glaucoma & Nasal Therapies LLC Compositions and methods for treatment of glaucoma
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Intraocular Lenses Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CA2894992A1 (en) * 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
CA2911472A1 (en) 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
RU2016106377A (ru) * 2013-07-26 2017-08-31 Галдерма Ресерч Энд Девелопмент Способ лечения утолщения кожи
BR112016006848A2 (pt) 2013-10-07 2017-08-01 Teikoku Pharma Usa Inc métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
EP3154517B8 (en) 2014-06-11 2020-06-03 EPI Health, LLC Stabilized oxymetazoline formulations and their uses
US20150374686A1 (en) 2014-06-30 2015-12-31 Galderma S.A. Methods of Treating Flushing Associated with Carcinoid Tumors and Carcinoid Syndrome
RU2560698C1 (ru) * 2014-08-15 2015-08-20 Общество с ограниченной ответственностью "Уральский медико-химический центр" (ООО "УМХЦ") Средство наружной терапии больных акне
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
WO2017007910A1 (en) 2015-07-09 2017-01-12 Galderma S.A. Method of reducing hair loss associated with chemotherapy
FR3041537B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
WO2017085226A1 (en) * 2015-11-17 2017-05-26 Galderma Sa Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea
EP3434271B1 (en) * 2016-03-22 2020-08-26 Doris Maria Hexsel Use of pharmaceutical composition for the treatment of poikiloderma of civatte
EP3476393A4 (en) * 2016-06-28 2019-07-17 Doris Maria Hexsel USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA
CN109265448B (zh) * 2018-11-15 2020-09-15 三峡大学 一类含叔丁基的n-咪唑乙酰基二氢喹喔啉类衍生物，合成方法及其作为杀菌剂上的应用
WO2020170034A1 (en) 2019-02-19 2020-08-27 Sol-Gel Technologies Ltd. Method for long-term treatment of rosacea
WO2020222192A1 (en) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Methods of treating pruritus
IL287130B (en) 2019-05-01 2022-08-01 Clexio Biosciences Ltd Methods of treating pruritus
JP2023539595A (ja) * 2020-08-26 2023-09-15 オティカラ，インコーポレーテッド 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法
RU2766973C1 (ru) * 2021-10-05 2022-03-16 Татьяна Сергеевна Русина Способ сочетанной терапии розацеа эритематозно-телеангэктатического подтипа
WO2023130086A1 (en) * 2021-12-31 2023-07-06 Jss Research, Llc Compositions and methods for topical treatment of vascular conditions

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4256763A (en) 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
DE2924005C2 (de) * 1979-06-13 1984-07-05 Sanol Schwarz-Monheim Gmbh, 4019 Monheim Isosorbiddinitrat enthaltendes Mittel
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
IT1248014B (it) * 1991-06-07 1995-01-05 Inverni Della Beffa Spa Preparazioni oftalmiche a rilascio protratto
US5292517A (en) * 1992-02-25 1994-03-08 Allergan, Inc. pH sensitive, reversible gelling, copolymeric erodible drug delivery system
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
DE69431880T2 (de) * 1993-10-13 2003-09-18 Allergan, Inc. Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5693647A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US5620416A (en) * 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
EP0969790A2 (de) 1997-02-21 2000-01-12 Beiersdorf Aktiengesellschaft Zubereitungen für die behandlung von rosacea
AU747385C (en) * 1997-04-10 2003-01-30 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders
JPH1129482A (ja) 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
US6513247B1 (en) * 1997-05-29 2003-02-04 Ariel Krasik-Geiger Calibrated angle and depth scissors
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
AR020660A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
IN185228B (cs) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
WO2000076502A1 (en) 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
US6147102A (en) * 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
PT1252157E (pt) * 2000-01-31 2004-10-29 Pfizer Prod Inc Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
AU2001273269B2 (en) 2000-07-14 2005-08-11 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
ATE303156T1 (de) 2000-10-30 2005-09-15 Univ Zuerich Verwendung von gnrh-analogue zur behandlung der harninkontinenz
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
JP2004532853A (ja) * 2001-05-09 2004-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 酒さを治療する目的での組成物の使用
TNSN02063A1 (en) * 2001-07-07 2005-12-23 Egyptian Natural Oil Co Natoil The medical effect of jojoba oil
US7115724B2 (en) * 2001-08-22 2006-10-03 Wyeth Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor
US7704530B2 (en) * 2001-09-14 2010-04-27 Kenji Nakamura Antimicrobially treated material and methods of preventing coloring thereof
US6680062B2 (en) * 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
FR2862537B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
BRPI0511519A (pt) * 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
EP1989261B1 (en) * 2006-02-20 2012-07-18 Commonwealth Scientific and Industrial Research Organisation Method and composition for priming wood and natural fibres
CA2686604A1 (en) * 2007-05-09 2008-11-20 Salutria Pharmaceuticals Llc Spiro compounds for treatment of inflammatory disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
ES2627405T3 (es) * 2010-03-26 2017-07-28 Galderma Research & Development Composiciones que comprenden brimonidina para el tratamiento del eritema
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Also Published As

Publication number Publication date
AU2004242967A1 (en) 2004-12-09
ES2376172T3 (es) 2012-03-09
US7838563B2 (en) 2010-11-23
AU2004242967B2 (en) 2009-05-28
US20150202202A1 (en) 2015-07-23
LT2815748T (lt) 2020-11-25
HK1164126A1 (en) 2012-09-21
EP1631293B1 (en) 2011-10-26
DK2815748T3 (da) 2020-08-24
CN1829518B (zh) 2010-09-08
PL2815748T3 (pl) 2020-11-16
CN1829518A (zh) 2006-09-06
PL1631293T3 (pl) 2012-03-30
CA2530938C (en) 2011-12-13
CN101816793A (zh) 2010-09-01
HUE051833T2 (hu) 2021-03-29
US8231885B2 (en) 2012-07-31
HUS1400029I1 (hu) 2017-10-30
EP2388007B1 (en) 2015-06-24
US20120277241A1 (en) 2012-11-01
FR14C0056I2 (fr) 2016-12-23
US20130172359A1 (en) 2013-07-04
CN102743380B (zh) 2015-08-12
CY1123393T1 (el) 2021-12-31
US8426410B2 (en) 2013-04-23
SI1631293T2 (sl) 2015-02-27
EP2815748A1 (en) 2014-12-24
ES2376172T5 (es) 2015-01-08
ATE530185T1 (de) 2011-11-15
US7439241B2 (en) 2008-10-21
HK1204996A1 (en) 2015-12-11
PT1631293E (pt) 2012-02-01
CY1112242T1 (el) 2015-12-09
US8557817B2 (en) 2013-10-15
EP2388007A1 (en) 2011-11-23
CA2530938A1 (en) 2004-12-09
ES2547336T3 (es) 2015-10-05
LU92462I2 (fr) 2015-11-02
WO2004105703A2 (en) 2004-12-09
US20050276830A1 (en) 2005-12-15
EP2815748B1 (en) 2020-08-05
NZ544300A (en) 2009-03-31
US20060264515A1 (en) 2006-11-23
PL2388007T4 (pl) 2016-03-31
US20100227867A1 (en) 2010-09-09
US20040242588A1 (en) 2004-12-02
US8859551B2 (en) 2014-10-14
NO333468B1 (no) 2013-06-17
IL172612A (en) 2013-03-24
US20060171974A1 (en) 2006-08-03
AU2004242967C1 (en) 2015-12-24
EP1631293A4 (en) 2009-05-06
HK1084591A1 (en) 2006-08-04
DK1631293T4 (en) 2015-01-12
CN102743380A (zh) 2012-10-24
MXPA05014107A (es) 2006-03-17
CN101380321B (zh) 2013-03-27
DK1631293T3 (da) 2012-02-13
CY2014028I2 (el) 2015-12-09
PL2388007T3 (pl) 2016-01-29
PT2388007E (pt) 2015-10-14
CN101816793B (zh) 2012-08-15
US20100021402A1 (en) 2010-01-28
HRP20150957T1 (hr) 2015-11-20
EP1631293A2 (en) 2006-03-08
US20170216282A1 (en) 2017-08-03
CY2014028I1 (el) 2015-12-09
NO20056104L (no) 2006-02-03
US20100130502A1 (en) 2010-05-27
SI1631293T1 (sl) 2012-02-29
US20160220565A1 (en) 2016-08-04
SI2388007T1 (sl) 2016-01-29
WO2004105703A3 (en) 2005-03-17
US20130172358A1 (en) 2013-07-04
ES2812532T3 (es) 2021-03-17
PL1631293T5 (pl) 2015-04-30
EP1631293B2 (en) 2014-10-08
HUE027616T2 (en) 2016-11-28
US8993571B2 (en) 2015-03-31
PT2815748T (pt) 2020-08-31
SI2815748T1 (sl) 2020-11-30
DK2388007T3 (en) 2015-09-28
CN101380321A (zh) 2009-03-11

Similar Documents

Publication Publication Date Title
BE2013C075I2 (cs)
BE2013C070I2 (cs)
BE2013C067I2 (cs)
BE2013C038I2 (cs)
BE2013C036I2 (cs)
BE2011C030I2 (cs)
BE2013C034I2 (cs)
BE2012C053I2 (cs)
AU2002327736A1 (cs)
AU2002340206A1 (cs)
AU2002253451A1 (cs)
AU2002254171A1 (cs)
AU2002255066A1 (cs)
AU2002256398A1 (cs)
AU2002310561A1 (cs)
AU2002311957A1 (cs)
AU2002316235A1 (cs)
AU2002316511A1 (cs)
AU2002318342A1 (cs)
AU2002321535A1 (cs)
AU2002322913A1 (cs)
AU2002324323A1 (cs)
AU2002327042A1 (cs)
AU2002245368A1 (cs)
AU2002329412A1 (cs)